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Brief communicationThe diabetes medication Canagliﬂozin reduces
cancer cell proliferation by inhibiting
mitochondrial complex-I supported respirationLinda A. Villani 1, Brennan K. Smith 1, Katarina Marcinko 1, Rebecca J. Ford 1, Lindsay A. Broadﬁeld 1,
Alex E. Green 1, Vanessa P. Houde 2, Paola Muti 2, Theodoros Tsakiridis 2, Gregory R. Steinberg 1,3,*ABSTRACT
Objective: The sodium-glucose transporter 2 (SGLT2) inhibitors Canagliﬂozin and Dapagliﬂozin are recently approved medications for type 2
diabetes. Recent studies indicate that SGLT2 inhibitors may inhibit the growth of some cancer cells but the mechanism(s) remain unclear.
Methods: Cellular proliferation and clonogenic survival were used to assess the sensitivity of prostate and lung cancer cell growth to the SGLT2
inhibitors. Oxygen consumption, extracellular acidiﬁcation rate, cellular ATP, glucose uptake, lipogenesis, and phosphorylation of AMP-activated
protein kinase (AMPK), acetyl-CoA carboxylase, and the p70S6 kinase were assessed. Overexpression of a protein that maintains complex-I
supported mitochondrial respiration (NDI1) was used to establish the importance of this pathway for mediating the anti-proliferative effects of
Canagliﬂozin.
Results: Clinically achievable concentrations of Canagliﬂozin, but not Dapagliﬂozin, inhibit cellular proliferation and clonogenic survival of
prostate and lung cancer cells alone and in combination with ionizing radiation and the chemotherapy Docetaxel. Canagliﬂozin reduced glucose
uptake, mitochondrial complex-I supported respiration, ATP, and lipogenesis while increasing the activating phosphorylation of AMPK. The
overexpression of NDI1 blocked the anti-proliferative effects of Canagliﬂozin indicating reductions in mitochondrial respiration are critical for anti-
proliferative actions.
Conclusion: These data indicate that like the biguanide metformin, Canagliﬂozin not only lowers blood glucose but also inhibits complex-I
supported respiration and cellular proliferation in prostate and lung cancer cells. These observations support the initiation of studies evalu-
ating the clinical efﬁcacy of Canagliﬂozin on limiting tumorigenesis in pre-clinical animal models as well epidemiological studies on cancer
incidence relative to other glucose lowering therapies in clinical populations.
 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Phlorizin is a non-selective inhibitor of the sodium-glucose trans-
porters (SGLTs) that was ﬁrst isolated from the bark of apple trees.
While effective in lowering blood glucose by promoting glycosuria
through the inhibition of SGLT2 in the kidney, it also causes gastro-
intestinal distress as it concurrently targets intestinal SGLT1 [1]. This
adverse effect prompted the development of inhibitors with greater
afﬁnity for the SGLT2 isoform, such as Canagliﬂozin and Dapagliﬂozin,
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the biguanide metformin [2].
In addition to treating diabetes, metformin also inhibits cancer cell
growth [3] and is currently the subject of over 150 oncology trials [4].
While many molecular targets of metformin have been described, both
its anti-diabetic and anti-cancer effects have been proposed to involve
the inhibition of mitochondrial complex-I [5e7] and the subsequent
activation of the 50-adenosine monophosphate-activated protein ki-
nase (AMPK) [5,8,9]. Similar results have been observed with PPAR
gamma agonists [7,10,11]. AMPK is a master metabolic stress sensor
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increases catabolic processes to restore cellular energy homeostasis
[12,13]. This is achieved, in part, by inhibiting anabolic pathways
including the synthesis of proteins and lipids by limiting the activity of
the mammalian target of rapamycin complex 1 (mTORC1) and acetyl-
CoA carboxylase (ACC), respectively [14e16]. Notably, these two
pathways are commonly upregulated in many cancers [17,18]. Given
these attributes, the inhibition of mitochondrial function and activation
of AMPK may be important for limiting the growth of a variety of cancer
types, a concept which is consistent with recent studies indicating that
preservation of mitochondrial respiration blocks the inhibitory effects of
biguanides on cellular proliferation [19,20].
Recent studies indicated that the SGLT2 inhibitors Canagliﬂozin and
Dapagliﬂozin may inhibit the growth of pancreatic and colon cancer
cells, potentially through inhibition of SGLT2-mediated glucose uptake
[22,23]. However, in many tumors, the inhibition of glucose uptake
alone is not sufﬁcient to reduce cell viability/proliferation [24,25]; thus,
it is unclear whether this is the primary mechanism by which SGLT2
inhibitors limit growth. We have recently observed that Canagliﬂozin
activates AMPK by inhibiting mitochondrial respiration in human em-
bryonic kidney cells and primary mouse hepatocytes [26]. In the
current study, we ﬁnd that clinical concentrations of Canagliﬂozin, but
not Dapagliﬂozin, potently inhibit the growth of cancer cells and
potentiate the effects of cytotoxic therapies. These anti-cancer prop-
erties are dependent on the inhibition of complex-I supported mito-
chondrial respiration but not the activation of AMPK. These data
indicate that, like biguanides, Canagliﬂozin inhibits mitochondrial
respiration and cellular proliferation, suggesting that this type 2 dia-
betes medication may also have utility in preventing and treating
cancer.
2. MATERIALS AND METHODS
2.1. Cell lines, culture conditions and treatments
Human prostate (PC3, 22RV-1), lung (A549, H1299), breast (MCF-7),
colon (HCT116), liver (HepG2) and ovarian (SKOV-3) cancer cells were
purchased from the American Type Culture Collection (ATCC: Manassa,
VA). Phoenix-AMPHO cells were a kind gift from Dr. Xu-Dong Zhu.
Immortalized mouse embryonic ﬁbroblast (MEF) cells were produced
from primary MEF cells acquired from WT, AMPK b1KO, and ACC
double knock-in (DKI, genetic disruption of AMPK inhibitory phos-
phorylation sites on ACC1/2 (Ser79/212Ala)) mice as described [15].
A549, H1299, PC3, 22RV-1, HCT116 and SKOV-3 cells were cultured
in RPMI 1640 media, HepG2 and MCF-7 cells were cultured in MEM
media, and Phoenix-AMPHO and MEF cells were cultured in DMEM
media (Gibco: Mississauga, ON). Culture media were supplemented
with 10% (v/v) FBS and 1% (v/v) antibiotic-antimycotic (100) (Gibco:
Mississauga, ON). MCF-7 media was also supplemented with 1% (v/v)
non-essential amino acids (100) and 1% (v/v) sodium-pyruvate
(100) (Gibco: Mississauga, ON). All cells were maintained at 37 C
in 5% CO2. The NDI1 and control (pMXS) vectors were created as
previously described [20] and ampliﬁed in Phoenix-AMPHO cells.
Parental PC3 cells were infected to generate PC3-NDI1 and PC3-pMXS
stably transfected cell lines and maintained in 0.75 mM glucose as
described [20] before treatment with Canagliﬂozin and Phenformin for
4 h (lipogenesis assay) or 48 h (proliferation assay). The AMPK a1
dominant negative was created as previously described [27]. PC3 cells
were infected with adenovirus containing AdCre (control, AD-CRE) or
AMPK-a1 threonine 172 to aspartic acid (T172D) dominant negative
(AD-AMPKDN) as previously described [28] and treatments started
24 h post-infection. Media was supplemented with Galactose, Na-
Pyruvate or Na-Acetate (Sigma: Toronto, ON) as indicated. CellsMOLECULAR METABOLISM 5 (2016) 1048e1056  2016 The Author(s). Published by Elsevier GmbH. This is an
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Chemicals LLC), Docetaxel (Cayman: Ann Arbor, MI), ionizing radiation
or controls (Salicylate, Phenformin, Sigma: Toronto, ON). Working
solutions were prepared so that the vehicle comprised less than 0.1%
of the media.
2.2. Clonogenic survival assay
Cells were seeded at a density of 500e1000 cells/well into 12-well
plates and treated in triplicate. Colonies were allowed to form over
5e10 days. Cells were ﬁxed and stained with 0.5% crystal violet DNA
stain (Sigma: Toronto, ON) in 50% EtOH. Viable colonies (50 cells)
were counted.
2.3. Proliferation assay
Cells were seeded at a density of 1000e2000 cells/well into 96-well
plates and treated in quadruplicate for 48e72 h. Cells were ﬁxed with
10% formalin and stained with 0.5% crystal violet DNA stain in 20%
MeOH. Once dry, the intracellular stain was solubilized with 0.05 M
NaH2PO4 and the absorbance at 570 nm was measured.
2.4. Cell viability assay
Cells were seeded at a density of 6  104 cells/well into 6-well plates
and treated in duplicated. Cell viability of ﬂoating and adherent cells
was determined by trypan blue (Gibco: Mississauga, ON) exclusion
according to the manufacturer’s protocol after 72 h.
2.5. Lipogenesis assay
Cells were treated in triplicate with drugs prepared in 0.5 mM Na-
acetate and 10 mCi/mL [H3]-Na-acetate (Perkin Elmer) in supple-
mented media. After 4 h, plates were placed on ice, washed with ice
cold PBS, and snap frozen to physically disrupt cell membranes. Cells
were collected at room temperature and a methanol: chloroform (2:1)
solvent was used for lipid extraction as previously described [29].
2.6. 2-Deoxy-D-glucose uptake
Cells were treated in triplicate with drugs prepared in 2 nCi [H3]-2-DG
(Perkins Elmer) in HEPES buffer (140 mM NaCl, 20 mM HEPES-Na,
5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2, pH 7.4). After 10 min,
plates were placed on ice, washed with ice cold PBS, and snap frozen
in lysis buffer. Lysates were collected on ice and measured for
radioactive counts.
2.7. Extracellular acidiﬁcation assay
Cells were seeded at a density of 2.25  105 cells/well into 48-well
plates in quadruplicate. Once adherent, cells were washed with PBS
and incubated with “test media”: (bicarbonate-free, pyruvate-free
DMEM supplemented with 11 mM Glucose, 2 mM L-Glutamine and
25 mg/L phenol red, pH 7.8) in a SpectraMax M5/M5e microplate
reader at 37 C. The DOD 560e480 nm was measured in 9 locations
per well, every 5 min over 4 h. Treatments were injected into wells 1 h
into the incubation period. ECAR was determined by measuring rate of
change of the test media color.
2.8. Respiration assay
High-resolution respirometry was conducted on approximately
2.5  106 cells in duplicate, at 37 C (Oroboros Oxygraph-2k: Inns-
bruck, Austria). Cells were washed with PBS, collected in MiRO5 buffer
(110 mM sucrose, 60 mM potassium lactobionate, 20 mM HEPES,
10 mM KH2PO4, 3 mM MgCl2, 0.5 mM EGTA, 1 g/L BSA, pH 7.1), and
added to the chambers. Cells were permeabilized with Digitonin
(10 mg/million cells, Sigma: Toronto, ON) and then treated withopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1049
Brief communicationglutamate (5 mM), malate (2 mM) and ADP (5 mM) to measure
complex-I supported respiration (GMD), which was subsequently
conﬁrmed through blockade with the complex-I speciﬁc inhibitor
rotenone (0.5 mM). The change in respiration between GMD and the
residual respiration after treatment with rotenone was used for anal-
ysis. Cells were treated with succinate (10 mM) to measure complex-II
supported respiration, which was later inhibited by the complex-II
speciﬁc inhibitor malonate (5 mM). The change in respiration be-
tween succinate stimulated respiration, and the residual respiration
after malonate treatment was used for analysis.
2.9. Cellular ATP assay
Cells were seeded at a density of 2  104 cells/well into white-walled
96-well plates and treated in duplicate for 30 min. The Abcam
Luminescent ATP Detection Kit (ab113849) was used according to the
manufacturer’s protocol.
2.10. Quantitative real-time PCR
A Roche High Pure RNA Isolation Kit was used to extract RNA from
cells. To eliminate genomic DNA, samples were incubated with a
solution of DNase I endonuclease. RNA quantity (ng/mL) and purity
(A260/A280) were assessed using a spectrophotometer. cDNA was
synthesized using SuperScript III reverse transcriptase (Life Technol-
ogies #18080-044) according to the manufacturer’s protocol. Ampli-
ﬁcation and detection was performed using a qPCR thermocycler
(Corbett Rotor Gene 6000), TaqMan probes (SLC5A2 #
Hs00894642_m1, 18S # Hs99999901_s1) and TaqMan MasterMix
(#4369016). Values were corrected to a housekeeping gene (18S). The
expression of the gene of interest was calculated using the 2DDCt
approach.
2.11. Western blotting and densitometry
Cells were treated in duplicate, washed in ice-cold PBS, and collected
in ice-cold lysis buffer (1 mM DTT, 1 mM Na3VO4, 20% triton-X, 1%
protease inhibitor cocktail tablet (Roche), 50 mM HEPES, 150 mM
NaCl, 100 mM NaF, 10 mM Na pyrophosphate, 5 mM EDTA, 250 mM
Sucrose). Samples were snap frozen, thawed, and manually collected
on ice. Working samples were prepared with 4 SDS sample buffer
(8% SDS, 0.25% Bromophenol Blue, 35% Glycerol, 250 mM TriseHCl
(pH 6.8), 1:20 1 M DTT). Boiled protein sample was separated using
SDS-PAGE. Proteins were electrically transferred at 4 C onto a
nitrocellulose membranes using 10% (v/v) MeOH transfer buffer.
Membranes were blocked (5% BSA solution in TBST (50 mM Tris,
150 mM NaCl, 1 M HCl, pH 7.4, 0.1% Tween-20)) and incubated with
the indicated primary and complementary HRP-conjugated secondary
antibodies. Antibodies were purchased from Cell Signaling Technology.
Densitometry values were quantiﬁed using Image J software
(McMaster University Biophotonics Lab, Hamilton, ON) and are
expressed as percent of control.
2.12. Xenograft model and tissue handling
The McMaster University Animal Ethics Research Board approved all
animal procedures. Male BALB/c-Nude mice (5 week, Charles-River:
Mississauga, ON) were housed in a pathogen-free facility under a
12 h light/dark cycle at 23 C, with ad libitum access to radiated chow
and water. Mice were subcutaneously grafted with 1  106 PC3 cells
into the right and left ﬂank. Tumor dimensions were measured with a
caliper. Volumes were calculated using the following equation: 1/
2(W2  L), where W and L are the measured width and length,
respectively. When tumor volumes reached 100e150 mm3, mice were
randomly divided into two groups: (1) vehicle (saline solution containing1050 MOLECULARMETABOLISM5 (2016) 1048e1056  2016 The Author(s). Published by Elsevier GmbH. T0.5% carboxymethyl cellulose, 0.025% Tween-20) or (2) 100 mg/kg
Canagliﬂozin. Mice were fasted overnight (12 h) and re-fed with chow
for 2 h before being gavaged with either Canagliﬂozin or vehicle (10 mL/
g body weight). Food was withdrawn again during the 5-hour treatment.
Tumors were then extracted and immediately snap frozen in liquid
nitrogen. Tumors were crushed, collected in lysis buffer and immedi-
ately homogenized for protein extraction and western blotting analysis.
2.13. Statistical analysis
All results are expressed as a mean with standard error of the mean
(SEM). A p value <0.05 was considered signiﬁcant (*). Statistical
analyses were performed using student t-test, one-way or two-way
ANOVA as appropriate. Bonferroni’s or Fisher LSD multiple compari-
son tests were used after the ANOVA. Clonogenic and proliferative IC50
values were calculated using a non-linear regression model with
normalized slope.
3. RESULTS
3.1. Canagliﬂozin blocks the cellular proliferation and clonogenic
survival of cancer cells
Clinically achievable concentrations of Canagliﬂozin and Dapagliﬂozin
range from 5 to 30 mM [2]. We found that within this clinical window of
exposure, Canagliﬂozin, but not Dapagliﬂozin, inhibited the prolifera-
tion and clonogenic survival of prostate (Figure 1AeB) and lung
(Figure 1CeD) cancer cells. These inhibitory effects were not due to
reductions in cell viability (Figure 1E). Similar observations were made
in cells derived from liver (HepG2) and breast (MCF7) cancers, while
the growth of those derived from colon (HCT116) and ovarian (SKOV-3)
cancers could only be inhibited at higher doses (Figure S1AeD).
Docetaxel and ionizing radiation induce cell death through microtubule
stabilization and the production of double stranded DNA breaks,
respectively, and are standard therapies for many cancers. We show
that the addition of Canagliﬂozin improved the efﬁcacy of both of these
treatments in prostate cancer cells (Figure 1FeG). These data indicate
that clinically relevant concentrations of Canagliﬂozin, but not Dapa-
gliﬂozin, potently suppress proliferation and clonogenic survival of
cancer cells alone and in combination with cytotoxic therapies.
3.2. Canagliﬂozin rapidly activates AMPK in cancer cells in vitro
and in vivo
While others [22] have reported the expression of SGLT2 in some
cancer cells, we observed very low mRNA expression in prostate and
lung cancer cells (Figure S2A), a ﬁnding consistent with the protein atlas
database [30]. However, despite low levels of SGLT2 expression we
found that Canagliﬂozin, but not Dapagliﬂozin, acutely and dose-
dependently decreased 2-deoxy-D-glucose (2-DG) uptake
(Figure S2B). To examine whether this inhibition of glucose uptake may
be important for the anti-proliferative effects of Canagliﬂozin, we
compared the proliferation of cells grown in standard media (11 mM) to
those grown in low glucose media (0.75 mM) or standard media
supplemented with pyruvate or acetate. We hypothesized that if Can-
agliﬂozin inhibited cell growth through inhibition of glucose uptake then
these effects would be ampliﬁed under low glucose conditions and
diminished following supplementation with pyruvate or acetate. Instead,
we found that the anti-proliferative effects of Canagliﬂozin were similar
under low glucose and pyruvate or acetate supplemented conditions
over 72 h, suggesting that the acute attenuation of glucose uptake is not
the primary factor suppressing proliferation (Figure S2CeD).
The inhibition of complex-I supported respiration can limit cellular
proliferation [19e21]. To examine whether this might be important forhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Clinically effective concentrations of Canagliﬂozin inhibit the proliferation and clonogenic survival of cancer cells. (A) Cellular proliferation of prostate cancer
cells (PC3 and 22RV-1) treated with Canagliﬂozin and Dapagliﬂozin and expressed relative to the vehicle controls for 72 h (n ¼ 3, in quadruplicate). (B) Clonogenic survival of
prostate cancer cells treated with Canagliﬂozin, Dapagliﬂozin or Salicylate and expressed relative to the vehicle controls. Representative images above and quantiﬁcations (n¼ 3, in
triplicate) shown below. (C) Cellular proliferation of lung cancer cells (A549 and H1299) treated with Canagliﬂozin and Dapagliﬂozin and expressed relative to the vehicle controls for
72 h (n ¼ 3, in quadruplicate). (D) Clonogenic survival of lung cancer cells treated with Canagliﬂozin, Dapagliﬂozin, or Salicylate and expressed relative to the vehicle controls.
Representative images above and quantiﬁcations (n ¼ 3, in triplicate) shown below. (E) Percentage of viable PC3 cells treated with Canagliﬂozin or vehicle over 72 h (n ¼ 5, in
duplicate). (F) Clonogenic survival of PC3 cells treated with Canagliﬂozin as a single agent or in combination with 0.5 nM Docetaxel (n ¼ 3, in triplicate). (G) Clonogenic survival of
PC3 cells treated with Canagliﬂozin as a single agent or in combination with 0, 2 or 4 Gy of radiation (n ¼ 3, in triplicate). Results are expressed as the mean and standard error of
the mean (SEM). Vehicle versus treatment * ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001, **** ¼ p < 0.0001 by one-way ANOVA for AeD, by two-way ANOVA for FeG. Single
versus combination treatment ## ¼ p < 0.01 by two-way ANOVA for FeG.mediating the effects of Canagliﬂozin, prostate cancer cells were
grown in galactose, a method used to enhance cellular reliance on
oxidative phosphorylation for ATP production [31]. When cells were
grown with galactose, Canagliﬂozin was approximately 50% more
efﬁcient at inhibiting growth compared to glucose alone (Figure 2A).
Similar effects were observed in H1299 lung cancer cells (Figure S2E).
Canagliﬂozin reduced cellular ATP under normal glucose conditions,
and this effect was more dramatic when cells were cultured in growth
media containing galactose (Figure 2B). Similar observations were
made with the biguanide phenformin (Figure 2B), suggesting that
Canagliﬂozin may be inhibiting mitochondrial respiration.
AMPK is acutely activated by reductions in cellular ATP [32]. We found
that Canagliﬂozin increased the activating phosphorylation of AMPKMOLECULAR METABOLISM 5 (2016) 1048e1056  2016 The Author(s). Published by Elsevier GmbH. This is an
www.molecularmetabolism.com(Thr172) byw4-fold within 30 min of treatment, an effect which was
maintained up to 24 h (Figure 2CeG). Canagliﬂozin also increased the
phosphorylation of ACC (Ser79) byw8-fold over the treatment period.
AMPK inhibits the activity of mTOR, and, consistent with this effect,
Canagliﬂozin rapidly decreased the phosphorylation of S6K (Thr389)
and its substrate S6 (Ser 240/244) by approximately 50%. In contrast,
Dapagliﬂozin did not alter the phosphorylation status of AMPK, ACC,
S6K, or S6 (Figure S3AeE). Given the rapid activation of AMPK, we
subsequently performed a doseeresponse with both SGLT2 inhibitors
at 0.5 h and found that, consistent with the inhibition of proliferation
and clonogenic survival, Canagliﬂozin, but not Dapagliﬂozin, dose-
dependently increased the phosphorylation of AMPK and ACC
(Figure 2HeJ and Figure S3FeH). Consistent with increased ACCopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1051
Figure 2: Canagliﬂozin activates AMPK in cancer cells in vitro and in vivo. (A) Cellular proliferation of PC3 cells maintained in 11 mM glucose or 10 mM galactose, treated with
Canagliﬂozin and expressed relative to the vehicle controls for 72 h (n¼ 3, in quadruplicate). (B) Cellular ATP (mM) in PC3 cellsmaintained in 11mMglucose or 10mMgalactose for 24 h, then
treated with Canagliﬂozin or Phenformin for 30 min and expressed relative to the vehicle controls (n¼ 4, in duplicate). (C) Representative western blot of Canagliﬂozin treated PC3 cells.
Canagliﬂozin (30 mM) increases pAMPK and pACC and reduces pS6k and pS6. (DeG) Quantiﬁcation of (C) (n¼ 3e6, in duplicate). (H) Canagliﬂozin dose-dependently increases pAMPK and
pACC in PC3 cells after 30 min (IeJ). Quantiﬁcation of (H) (n¼ 3e6, in duplicate). (K) Rate of lipogenesis (nmol of H3-acetate incorporation into fatty acid/mg of protein/hour) in PC3 cells
treated with Canagliﬂozin (30 mM) for 4 h relative to the vehicle control (n¼ 3, in triplicate). (L) 100 mg/kg Canagliﬂozin administered by oral gavage increases pAMPK and pACC in PC3
xenografts of BALB/c-nude mice (densitometry units of pACC/ACC and pAMPK/AMPK stated above blot image). (M) Cellular proliferation of PC3 cells infected with empty vector (AD-CRE) or
dominant negative AMPK (AD-AMPKDN), treated with Canagliﬂozin and expressed relative to vehicle controls for 72 h (n¼ 6, in quadruplicate). (N) Cellular proliferation of WT, ACCDKI and
AMPKb1KOMEF cells treated with Canagliﬂozin and expressed relative to the vehicle controls for 72 h (n¼ 3, in quadruplicate). Results are expressed as themean and standard error of the
mean (SEM). Galactose versus glucose ##¼ p < 0.01 by two-way ANOVA for A, * ¼ p < 0.05, ** ¼ p < 0.01, ****¼ p < 0.0001 by two-way ANOVA for B. Vehicle versus treatment
* ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001, **** ¼ p < 0.0001 by one-way ANOVA for DeG and IeJ, by t-test for K.
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phosphorylation and reductions in cellular ATP, Canagliﬂozin potently
inhibited the synthesis of fatty acids derived from acetate (Figure 2K),
indicating that the inhibition of lipogenesis was not related to the re-
ductions in glucose uptake. Importantly, this activation of AMPK was
also observed in PC3 xenografts following a single oral dose of Can-
agliﬂozin (Figure 2L). However, this activation of AMPK did not appear
to be essential for mediating the anti-proliferative effects of Canagli-
ﬂozin, as they were not signiﬁcantly altered when a dominant-negative
AMPK was overexpressed (Figure 2M). Furthermore, the anti-
proliferative effects of Canagliﬂozin were comparable between
mouse embryonic ﬁbroblasts derived from wildtype mice or those
lacking the b1 subunit of AMPK (AMPK b1KO [15,33]) or the key
regulatory AMPK phosphorylation sites on ACC (ACCDKI [29]), which
are essential for AMPK regulation of lipid synthesis (Figure 2N).
3.3. Inhibition of complex-I supported respiration is important for
the anti-proliferative effects of Canagliﬂozin
Recent studies have indicated that the inhibition of mitochondrial
complex-I is vital for mediating the anti-proliferative effects of
biguanides [19,20] and that these effects are independent of AMPK
[21]. We examined the effects of Canagliﬂozin on oxidative phos-
phorylation in cancer cells grown under standard glucose conditions
and found that it induced greater acidiﬁcation of the media compared
to vehicle or Dapagliﬂozin (Figure 3A). We then examined respiration
using permeabilized PC3 prostate cancer cells (a method which is not
dependent on substrate delivery) and found that Canagliﬂozin dose-
dependently reduced oxygen consumption through inhibition of
complex-I (starting at concentrations as low as 5 mM) without
affecting complex-II (Figure 3BeC). In contrast, Dapagliﬂozin had
minimal effects on complex-I supported respiration within the ther-
apeutic window of exposure and did not affect complex-II
(Figure 3BeC).
To establish whether the inhibition of complex-I was important for
mediating the anti-lipogenic and anti-proliferative effects of Canagli-
ﬂozin, we expressed the Saccharomyces cerevisiae NADH dehydro-
genase NDI1 (Figure 3D), which can maintain respiration in the
presence of complex-I inhibitors (including rotenone, or biguanides) in
mammalian cells [19,20,34]. Remarkably, we found that expression of
NDI1 rescued the inhibitory effects of Canagliﬂozin on lipogenesis
(Figure 3E) and made cells completely refractory to the inhibitory ef-
fects of Canagliﬂozin on cellular proliferation compared to controls
(Figure 3F). These data indicate that Canagliﬂozin limits cancer cell
proliferation by inhibiting complex-I supported respiration.
4. DISCUSSION
We ﬁnd that Canagliﬂozin, but not Dapagliﬂozin, inhibits the prolifer-
ation and clonogenic survival of prostate and lung cancer cells. Can-
agliﬂozin also enhanced the effectiveness of Docetaxel and ionizing
radiation to inhibit clonogenic survival. Despite similar potencies for
inhibiting SGLT2 [2], Canagliﬂozin, but not Dapagliﬂozin, decreased 2-
DG uptake, inhibited complex-I supported mitochondrial respiration,
reduced cellular ATP, and activated AMPK. Activation of AMPK was
also observed in cancer xenographs following an acute oral gavage of
mice with Canagliﬂozin. Importantly, the anti-proliferative effects of
Canagliﬂozin were completely reversed following overexpression of
NDI1, thus indicating that the inhibition of mitochondrial complex-I is
required for the inhibitory effects of Canagliﬂozin on cancer cell
proliferation.
The anti-proliferative effects of Canagliﬂozin were similar under both
high and low glucose conditions and following supplementation of theMOLECULAR METABOLISM 5 (2016) 1048e1056  2016 The Author(s). Published by Elsevier GmbH. This is an
www.molecularmetabolism.commedia with pyruvate or acetate, suggesting substrate for oxidative
phosphorylation or lipogenesis was not the primary factor limiting
proliferation. Previous studies have shown that compared to Dapa-
gliﬂozin, Canagliﬂozin has a higher afﬁnity for inhibiting SGLT1 [2], and
may also inhibit the glucose transporter GLUT1 [35]. While both SGLT1
[36] and GLUT1 [37] may be expressed in prostate cancer cells,
previous studies have indicated that inhibiting glucose uptake in PC3
cells is insufﬁcient to inhibit cellular proliferation [24]. Collectively,
these data suggest that the inhibition of glucose uptake is unlikely to
be the primary mechanism mediating the inhibition of cellular prolif-
eration; however, as discussed below, it may be an important
contributing factor.
We found that Canagliﬂozin increased media acidiﬁcation and reduced
ATP levels under standard glucose conditions, effects that were
associated with the inhibition of mitochondrial complex-I. The anti-
proliferative effects of Canagliﬂozin were also enhanced when the
media was switched to galactose, a fuel that yields no net ATP when
oxidized through glycolysis, suggesting that the inhibition of mito-
chondrial respiration was responsible for mediating the anti-
proliferative effects. Consistent with this concept when the block in
complex-I was circumvented by the expression of NDI1, Canagliﬂozin
failed to decrease cellular proliferation. These data indicate that the
inhibition of complex-I is vital for Canagliﬂozin to inhibit cellular pro-
liferative capacity, but it is possible that simultaneous reductions in
glucose uptake may also be important. For example, inhibiting glucose
uptake with 2-DG and blocking complex-I supported respiration
simultaneously with either metformin or rotenone dramatically en-
hances the ability of complex-I inhibitors to reduce cellular proliferation
[25]. These data suggest that since Canagliﬂozin inhibits both glucose
uptake and complex-I supported respiration simultaneously, this dual
mechanism of action may be important for mediating the inhibitory
effects on proliferation. The structural components that differentiate
Canagliﬂozin from Dapagliﬂozin to mediate these effects of on glucose
uptake and mitochondrial respiration are currently unknown but will be
the subject of future studies.
Consistent with the effects of clinically relevant concentrations of
Canagliﬂozin on inhibiting mitochondrial function and reducing cellular
ATP, we ﬁnd that it rapidly and robustly increased AMPK activity in
cultured cells in vitro. Importantly, this effect was also observed in
cancer xenographs following a single, acute oral gavage to mice. The
activation of AMPK by Canagliﬂozin also increased phosphorylation of
ACC at Ser79, a site that is regulated by AMPK to inhibit lipid synthesis
[29]. However, in contrast to the effects observed when overexpressing
NDI1, overexpressing a dominant negative AMPK or blocking AMPK’s
ability to phosphorylate and inhibit ACC did not impair Canagliﬂozin’s
ability to reduce cellular proliferation. Consistent with an AMPK-
independent effect, Canagliﬂozin also inhibited the growth of A549
cells, which lack the upstream AMPK activator and tumor suppressor
liver kinase B1 (LKB1) [13]. These data suggest that the activation of
AMPK and phosphorylation of ACC are not essential for the anti-
proliferative effects of Canagliﬂozin, ﬁndings that are consistent with
a recent study indicating that blocking mitochondrial function, but not
AMPK, is critical for mediating the anti-proliferative effects of met-
formin [21]. These ﬁndings are also consistent with the observed
reduction in cellular ATP induced by Canagliﬂozin and previous ob-
servations that ATP is a vital cofactor for lipid synthesis that is required
for cellular proliferation [38,39]. In addition, the inhibition of complex-I
supported respiration also increases the production of reactive oxygen
species and reduces cancer cell growth [40], suggesting this may be
an additional mechanism by which Canagliﬂozin exerts anti-
proliferative effects.open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1053
Figure 3: Canagliﬂozin inhibits mitochondrial complex-I to limit cancer cell proliferation. (A) Extracellular acidiﬁcation rate (ECAR, mOD/min) of PC3 cells 3 h post treatment
with Canagliﬂozin (30 mM), Dapagliﬂozin (30 mM), or vehicle (n ¼ 4, in quadruplicate). (B) Rate of oxygen consumption (pmol/s/106 cells) through complex-I of permeabilized PC3
cells treated with increasing concentrations of Canagliﬂozin and Dapagliﬂozin (n ¼ 4, in duplicate). (C) Rate of oxygen consumption (pmol/s/106 cells) through complex-II of
permeabilized PC3 cells treated with increasing concentrations of Canagliﬂozin and Dapagliﬂozin (n ¼ 4, in duplicate). (D) Western blot analysis of NDI1 expression in PC3-pMXS
and PC3-NDI1 cells. (E) Rate of lipogenesis (nmol of [H3-acetate] incorporation into fatty acid/mg of protein/hour) in PC3-pMXS and PC3-NDI1 cells treated with Canagliﬂozin
(30 mM) for 4 h relative to the vehicle control (n ¼ 3, in triplicate). (F) Cellular proliferation of PC3-PMXS and PC3-NDI1 cells treated with Canagliﬂozin or Phenformin and expressed
relative to the vehicle controls for 48 h (n ¼ 4, in quadruplicate). (G) Graphical representation of the proposed mechanism of Canagliﬂozin. Results are expressed as the mean and
standard error of the mean (SEM). Vehicle versus treatment ** ¼ p < 0.01, *** ¼ p < 0.001, **** ¼ p < 0.0001 by one-way ANOVA for A, by two-way ANOVA for B. Canagliﬂozin
versus Dapagliﬂozin #### ¼ p < 0.0001 by two-way ANOVA for B. pMXS versus NDI1 * ¼ p < 0.05, ** ¼ p < 0.01 by t-test for E, by two-way ANOVA for F.
Brief communication5. CONCLUSION
Targeting mitochondrial energetics and metabolic checkpoints has
emerged as an important modality for treating a multitude of cancers
[15,41]. Our ﬁndings indicate that clinically achievable concentrations
of Canagliﬂozin inhibit multiple pathways essential for cancer cell
proliferation. Future studies examining the effects of Canagliﬂozin on1054 MOLECULARMETABOLISM5 (2016) 1048e1056  2016 The Author(s). Published by Elsevier GmbH. Tcancer xenograph growth in SGLT2 null mice will be important to
determine the impact of this therapy on cancer growth independently
of systemic reductions in circulating blood glucose induced by
glycosuria. Our studies also support the initiation of epidemiological
studies examining the effects of Canagliﬂozin on cancer incidence
relative to other glucose lowering therapies in patients with diabetes.
These studies may lay the foundation for clinical trials investigating thehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
use of this well-tolerated therapy alone and in combination with other
standard of care treatments.
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